In my humble opinion, thinking about that editorial, it is probably the most consequential editorial by a notable doctor on a FDA panel, I have ever heard about.
Further to the arguments in the NYT op-ed, FDA approval of Aducanumab would have a deleterious and cascading effect on the clinical development of safe and effective AD drugs.
Some phase-3 trials of subsequent AD drug candidates would likely have a goal of showing non-inferiority to Aducanumab, and such a soft endpoint could enable cascading FDA approvals of AD drugs that have no efficacy whatsoever.
In short, FDA approval of Aducanumab would be a categorical disaster, IMO.
Market Data 
Markets 
AI
